Anderson Hoagland & Co’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-18,610
Closed -$1.8M 89
2019
Q3
$1.8M Buy
18,610
+6,034
+48% +$573K 1.09% 24
2019
Q2
$1.18M Sell
12,576
-3,724
-23% -$354K 0.73% 42
2019
Q1
$1.44M Buy
16,300
+559
+4% +$48.9K 0.87% 35
2018
Q4
$1.02M Buy
15,741
+440
+3% +$32.5K 0.72% 43
2018
Q3
$1.39M Buy
15,301
+551
+4% +$48.7K 0.78% 39
2018
Q2
$1.17M Sell
14,750
-32
-0.2% -$2.66K 0.65% 50
2018
Q1
$1.32M Buy
14,782
+55
+0.4% +$5.28K 0.76% 43
2017
Q4
$1.54M Sell
14,727
-660
-4% -$74.5K 0.9% 38
2017
Q3
$2.24M Buy
15,387
+343
+2% +$46.7K 1.38% 22
2017
Q2
$1.95M Buy
15,044
+2,754
+22% +$337K 1.25% 27
2017
Q1
$1.53M Hold
12,290
0.82% 50
2016
Q4
$1.42M Buy
12,290
+40
+0.3% +$4.46K 0.83% 47
2016
Q3
$1.28M Hold
12,250
0.73% 51
2016
Q2
$1.21M Hold
12,250
0.74% 48
2016
Q1
$1.23M Buy
12,250
+2,500
+26% +$257K 0.76% 43
2015
Q4
$1.17M Hold
9,750
0.72% 44
2015
Q3
$1.05M Hold
9,750
0.67% 45
2015
Q2
$1.13M Hold
9,750
0.66% 48
2015
Q1
$1.05M Hold
9,750
0.61% 45
2014
Q4
$1.09M Hold
9,750
0.66% 43
2014
Q3
$926K Buy
9,750
+4,875
+100% +$440K 0.57% 48
2014
Q2
$419K Sell
4,875
-4,875
-50% -$371K 0.27% 89
2014
Q1
$681K Hold
9,750
0.45% 54
2013
Q4
$824K Hold
9,750
0.57% 47
2013
Q3
$751K Buy
+9,750
New +$683K 0.52% 48

Other funds holding CELG

Anderson Hoagland & Co's CELG Position: Q4 2019 in Review

Anderson Hoagland & Co sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 18,610 shares — an estimated $1.8M sold.

Anderson Hoagland & Co first reported a position in CELG in Q3 2013 and held it in 25 quarters. The position peaked at $2.24M in Q3 2017. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • Anderson Hoagland & Co reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • Anderson Hoagland & Co sold 18,610 Celgene Corp shares in Q4 2019, an estimated $1.8M.
  • Anderson Hoagland & Co first reported a position in Celgene Corp in Q3 2013 and held it in 25 quarters.
  • Anderson Hoagland & Co's Celgene Corp position peaked at $2.24M in Q3 2017.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on Anderson Hoagland & Co's 13F filing for Q4 2019, filed 6 Jan 2020.